Astrocytoma Treatments
Find Astrocytoma Treatments
Medications for Astrocytoma
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Astrocytoma.
Found 4 Approved Drugs for Astrocytoma
Temodar
Generic Name
Temozolomide
Temodar
Generic Name
Temozolomide
Form: Injection, Capsule
Method of administration: Oral, Intravenous
FDA approval date: August 11, 1999
Classification: Alkylating Drug
TEMODAR is an alkylating drug indicated for the treatment of adult patients with: Newly diagnosed glioblastoma concomitantly with radiotherapy and then as maintenance treatment.
Bevacizumab
Brand Names
Alymsys, Avastin, Jobevne, Lytenava, MVASI, Vegzelma, Zirabev
Bevacizumab
Brand Names
Alymsys, Avastin, Jobevne, Lytenava, MVASI, Vegzelma, Zirabev
Form: Injection
Method of administration: Intravenous, Intravitreal, Intravascular
FDA approval date: February 26, 2004
Classification: Vascular Endothelial Growth Factor Inhibitor
Alymsys is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment.
Gliadel
Generic Name
Carmustine
Gliadel
Generic Name
Carmustine
Form: Kit, Wafer
Method of administration: Intravenous, Intracavitary
FDA approval date: December 13, 2012
Classification: Alkylating Drug
GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade glioma as an adjunct to surgery and radiation, and recurrent glioblastoma as an adjunct to surgery. GLIADEL Wafer is an alkylating drug indicated for the treatment of: newly-diagnosed high-grade glioma as an adjunct to surgery and radiation ( 1 ) and recurrent glioblastoma as an adjunct to surgery ( 1 )
Everolimus
Brand Names
Afinitor, Afinitor Disperz, Torpenz, Yulithira, Zortress
Everolimus
Brand Names
Afinitor, Afinitor Disperz, Torpenz, Yulithira, Zortress
Form: Tablet
Method of administration: Oral
FDA approval date: March 31, 2009
Classification: mTOR Inhibitor Immunosuppressant
AFINITOR is a kinase inhibitor indicated for the treatment of: Postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole.
Showing 1-4 of 4
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances